ClinicalTrials.gg
CompletedNCT02545842Updated Apr 25, 2022

Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)

A Phase 4 interventional study of INSULIN GLARGINE in Type 2 Diabetes Mellitus, sponsored by Sanofi. Completed at 44 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-04-25.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
947
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Enrollment
10th of 175
947 · median 253
Started
2015
with 13 others
Phase 4
103 of 176
2 open now
Registered
127th of 176
by date
Lead sponsor
82 of 176
Sanofi

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 10th largest by enrollment of the 175 interventional ones that give a count, is one of 14 that started in 2015, is one of 103 in phase 4, and was the 127th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Primary Objective:

To identify a best fasting plasma glucose (FPG) target for Chinese type 2 diabetes patients using insulin glargine which can provide the highest control rate of glycated hemoglobin (HbA1c) \< 7%.

Secondary Objectives:

The control rate of HbA1c ≤6.5% achievement. The control rate of HbA1c \<7.0% in patients achieving their FPG target. The percentage of HbA1c \<7% without hypoglycemia. The percentage of patients achieving the FPG target without hypoglycemia. The percentage of patients achieving the FPG target and post prandial glucose (PPG) target (2-hour post breakfast \<10 mmol/L).

Read the detailed description

The study duration for each patient will be 27 weeks.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 65 years old.
  • Type 2 diabetes patients insufficient controlled by 1-3 oral anti-hyperglycemic drugs (OADs) with stable dose at least 3 months:
  • If on 1 OAD, provided with the following doses (including but not limited to):

    • α-glucosidase inhibitor: 100mg, three times a day (tid);
    • metformin: 1.5-2.0 g/day;
    • sulphonylureas: sub-maximum (half dose above) to maximum tolerated dose;
    • thiazolidinediones: eg. pioglitazone, 30-40 mg/day.
    • Besides the medications listed above, if on 1 OAD, others should be maximum tolerated dose allowed in package insert.
  • If on 2-3 OADs, any range of dose is acceptable.
  • >7%, and ≤10.5%.
  • FPG >7 mmol/L.
  • (BMI) ≥20 kg/m\^2, and ≤40 kg/m\^2.
  • Diabetes duration ≥1 year.
  • Physician decides to and the patient is willing to start basal insulin (BI) treatment.
  • Willing to join the study and sign the .

Exclusion criteria

Exclusion criteria:

  • Type 1 diabetes patients.
  • Patients with acute diabetic complications (including unexplained severe hypoglycemia in the last 6 months).
  • Previous treatment with insulin for more than 1 month cumulatively in last 1 year, or treatment with insulin in the last 3 months before the screening.
  • Known hypoglycemia unawareness or recurrent hypoglycemia.
  • to study drug or its .
  • Any acute major organ or systemic disease, or any other situation judged by the Investigator, that is difficult for the 24 weeks follow-up.
  • Pregnancy or breastfeeding women.
  • Have any mental disorders, lack self-control or not able to express accurately.
  • Involved in another clinical trial simultaneously or within a 1 month before start of trial.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
947 participants (actual)

Study arms

  • Experimental
    Group 1

    Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of \<=5.6 mmol/L

    Drug: INSULIN GLARGINE

  • Experimental
    Group 2

    Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of \<=6.1 mmol/L

    Drug: INSULIN GLARGINE

  • Experimental
    Group 3

    Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of \<=7.0 mmol/L

    Drug: INSULIN GLARGINE

Interventions

  • Pharmaceutical form: solution Route of administration: subcutaneous

    Also known as: HOE901

06

What researchers measure

Primary outcomes

  1. Percentage of patients with HbA1c <7% achievement

    Time frame: 24 weeks

Secondary outcomes

  1. Percentage of patients achieving HbA1c <=6.5%

    Time frame: 24 weeks

  2. Percentage of patients achieving FPG target with HbA1c <7%

    Time frame: 24 weeks

  3. Percentage of patients achieving HbA1c <7% without hypoglycemia

    Time frame: 24 weeks

  4. Percentage of patients achieving the FPG target without hypoglycemia

    Time frame: 24 weeks

  5. Percentage of patients achieving FPG target

    Time frame: 24 weeks

  6. Percentage of patients achieving PPG target (2-hour post-breakfast <10 mmol/L)

    Time frame: 24 weeks

  7. Change from baseline in HbA1c

    Time frame: Baseline to 24 weeks

  8. Change in FPG

    Time frame: 8 weeks to 24 weeks

  9. Change in PPG

    Time frame: Baseline to 24 weeks

  10. Change in insulin doses in each arm

    Time frame: 1 week to 24 weeks

  11. Change in body weight in each treatment arm

    Time frame: Baseline to 24 weeks

  12. Percentage of patients experienced hypoglycemic events

    Time frame: 24 weeks

07

Study locations

44 sites
  • Investigational Site Number 156053
    Anshan, China
  • Investigational Site Number 156001
    Beijing, China
  • Investigational Site Number 156002
    Beijing, China
  • Investigational Site Number 156006
    Beijing, China
  • Investigational Site Number 156013
    Changchun, 130033, China
  • Investigational Site Number 156014
    Changchun, 130033, China
  • Investigational Site Number 156022
    Changde, 415000, China
  • Investigational Site Number 156017
    Changsha, China
  • Investigational Site Number 156034
    Changzhou, China
  • Investigational Site Number 156023
    Chenzhou, China
  • Investigational Site Number 156026
    Guangzhou, 510515, China
  • Investigational Site Number 156029
    Haikou, 570102, China
  • Investigational Site Number 156028
    Haikou, China
  • Investigational Site Number 156040
    Haikou, China
  • Investigational Site Number 156039
    Hangzhou, 310013, China
  • Investigational Site Number 156038
    Hangzhou, China
  • Investigational Site Number 156042
    Hangzhou, China
  • Investigational Site Number 156044
    Hangzhou, China
  • Investigational Site Number 156048
    Hefei, China
  • Investigational Site Number 156050
    Hefei, China
  • Investigational Site Number 156011
    Kunming, China
  • Investigational Site Number 156052
    Kunming, China
  • Investigational Site Number 156016
    Lanzhou, China
  • Investigational Site Number 156041
    Lishui, China
  • Investigational Site Number 156020
    Nanchang, 330006, China
  • Investigational Site Number 156018
    Nanchang, China
  • Investigational Site Number 156019
    Nanchang, China
  • Investigational Site Number 156031
    Nanjing, China
  • Investigational Site Number 156043
    Nanjing, China
  • Investigational Site Number 156049
    Nanjing, China
  • Investigational Site Number 156035
    Shanghai, China
  • Investigational Site Number 156036
    Shanghai, China
  • Investigational Site Number 156047
    Shanghai, China
  • Investigational Site Number 156027
    Shantou, China
  • Investigational Site Number 156015
    Shenyang, China
  • Investigational Site Number 156054
    Shijiazhuang, China
  • Investigational Site Number 156007
    Tangshan, 063000, China
  • Investigational Site Number 156010
    Tianjin, 300032, China
  • Investigational Site Number 156055
    Wuhan, 430000, China
  • Investigational Site Number 156037
    Xuzhou, China
  • Investigational Site Number 156033
    Yangzhou, China
  • Investigational Site Number 156030
    Yueyang, China
  • Investigational Site Number 156032
    Zhenjiang, 212001, China
  • Investigational Site Number 156025
    Zhuzhou, 412000, China
08

References and documents

Publications

  • Wang X, Wu G, Shen D, Zhang X, Yang W. Unmet Needs of Glycaemic Control and Risk Factors of Residual Hyperglycaemia in a Chinese Population with Type 2 Diabetes Initiating Basal Insulin: A Post Hoc Analysis of the FPG GOAL Study. Adv Ther. 2022 Jun;39(6):2820-2830. doi: 10.1007/s12325-022-02128-y. Epub 2022 Apr 16. PubMed 35430674 ↗
  • Li L, Yang T, Xue Y, Ruan P, Du J, Li Y, Zhang X, Cui N, Yang W. Influence of Fasting Plasma Glucose Targets on Glycemic Variability in Chinese Participants With Type 2 Diabetes: A Post Hoc Analysis of the FPG GOAL Trial (BEYOND III). Adv Ther. 2022 Jan;39(1):421-429. doi: 10.1007/s12325-021-01932-2. Epub 2021 Nov 10. PubMed 34757600 ↗
  • Ma J, Lei M, Li Y, Zhang X, Cui N, Yang W. Influence of Fasting Glucose Levels on Achieving Glycemic Target in Individuals with Type 2 Diabetes: a Post Hoc Analysis. Adv Ther. 2020 Sep;37(9):3816-3826. doi: 10.1007/s12325-020-01410-1. Epub 2020 Jul 15. PubMed 32671687 ↗
  • Yang W, Yang Z, Zhao J, Lu H, Luo T. Assessment of three fasting plasma glucose targets for insulin glargine-based therapy in people with type 2 diabetes mellitus in China: study protocol for a randomized controlled trial. Trials. 2016 Sep 26;17(1):470. doi: 10.1186/s13063-016-1588-6. PubMed 27669747 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2015, a primary completion of Apr 2018 and a completion of Apr 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2015
First posted
Sep 10, 2015
Start
Sep 7, 2015
Primary completionActual
Apr 20, 2018
CompletionActual
Apr 20, 2018
Last update
Apr 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02545842
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Sep 10, 2015
Start date
Sep 7, 2015
Primary completion
Apr 20, 2018
Completion
Apr 20, 2018
Last update
Apr 25, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion